Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

  title={Platinum-based chemotherapy for variant castrate-resistant prostate cancer.},
  author={Ana Aparicio and Andrea Lynne Harzstark and Paul G. Corn and Sijin Wen and John Charles Araujo and Shi-ming Tu and Lance C. Pagliaro and Jeri Kim and Randall E. Millikan and Charles T. Ryan and Nizar M. Tannir and Amado J. Zurita and Paul Mathew and Wadih Arap and P. Brunny Troncoso and Peter F. Thall and Christopher J. Logothetis},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={19 13},
PURPOSE Clinical features characteristic of small-cell prostate carcinoma (SCPC), "anaplastic," often emerge during the progression of prostate cancer. We sought to determine the efficacy of platinum-based chemotherapy in patients meeting at least one of seven prospectively defined "anaplastic" clinical criteria, including exclusive visceral or predominantly lytic bone metastases, bulky tumor masses, low prostate-specific antigen levels relative to tumor burden, or short response to androgen… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS